Yantai LNC Biotechnology

Executive Summary

Yantai LNC Biotechnology (LNC) is a Chinese biotech company pioneering first-in-class theranostic radiopharmaceuticals for oncology. Founded in 2021 and headquartered in Yantai, the company employs 50-200 people and has raised $450 million to advance its proprietary dual-target drug development platform. LNC leverages pharmacokinetic optimization technologies to create precision radiopharmaceuticals that simultaneously enable diagnosis and therapy (theranostics). Its pipeline targets clinically validated biomarkers such as PSMA, FAP, and integrin αvβ3, addressing high unmet needs in prostate, pancreatic, and other cancers. With a Phase 3 stage asset, LNC is positioned to become a leader in the rapidly growing radiopharmaceutical market.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 data readout for PSMA-targeted theranostic candidate70% success
• Q1 2027IND filing for FAP-targeted therapy80% success
• H2 2026Strategic partnership or licensing deal for global commercialization60% success